HIV / AIDS
Immediate ART during Early HIV Infection May Delay Disease Progression
- Details
- Category: HIV Treatment
- Published on Friday, 16 December 2011 00:00
People who started combination antiretroviral therapy (ART) within 6 months of HIV infection were less likely to experience large CD4 cell decreases or AIDS-related illnesses during follow-up, although viral load set point could not be evaluated, researchers reported in the December 15, 2011 Journal of Infectious Diseases.
Math Model Suggests PrEP plus ART Would Lower HIV Drug Resistance
- Details
- Category: HIV Prevention
- Published on Tuesday, 13 December 2011 00:00
An appropriate combination of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) could potentially reduce the prevalence of drug-resistant HIV in resource-limited countries, but the wrong balance could increase resistance and the need for second-line therapy, according to a mathematical model described in the December 7, 2011, Nature Scientific Reports.
CDC Announces $300 Million in HIV Prevention Funding Grants
- Details
- Category: HIV Prevention
- Published on Saturday, 10 December 2011 00:00
The U.S. Centers for Disease Control and Prevention (CDC) last week announced the first round of grant awards to state and local health departments as part of its new "high-impact" HIV prevention initiative. The CDC launched the initiative earlier this year, emphasizing prevention efforts that target the most heavily impacted regions and population groups -- in particular young black gay men -- and are supported by scientific evidence.
Elvitegravir Continues to Look Good at 2 Years
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 December 2011 00:00
Gilead Sciences announced last week that its experimental integrase inhibitor elvitegravir continued to suppress HIV viral load as well as raltegravir (Isentress) in combination with a boosted protease inhibitor at 96 weeks in a Phase 3 study.
Experimental Vaccine Offers Partial Protection against HIV-Related Virus in Monkeys
- Details
- Category: HIV Vaccines
- Published on Saturday, 10 December 2011 00:00
An investigational adenovirus prime-poxvirus booster vaccine regimen reduced the likelihood of infection in rhesus monkeys exposed to simian immunodeficiency virus (SIV), a monkey virus similar to HIV, researchers reported in the January 4, 2011, advance online edition of Nature. The vaccine reduced infection risk by about 80% compared with placebo, and monkeys that did become infected had lower viral loads.
Occasional Marijuana Smoking Does Not Cause Long-Term Lung Damage
- Details
- Category: Alternative & Complementary Therapy
- Published on Saturday, 10 December 2011 00:00
Infrequent smoking of cannabis over prolonged periods did not lead to a decrease in pulmonary function, according to a 20-year study reported in the January 11, 2012, Journal of the American Medical Association. These findings suggest that occasional recreational use of marijuana does not cause lung damage similar to that seen with regular tobacco use, but more study is needed of people who use medical marijuana more frequently.
Activists Launch Survey for People with HIV about Cure Research Risk
- Details
- Category: Search for a Cure
- Published on Friday, 09 December 2011 00:00
Activists with Project Inform, the Program for Wellness, and the Treatment Action Group are asking HIV positive people to participate in a brief online survey about participation in clinical trials and opinions about the potential risks and benefits of cure-related research.
More Articles...
- Monkey Study at HIV Persistence Workshop Offers Hope for Functional Cure
- Truvada Drug Levels in Vaginal and Rectal Tissue Offer Clues to HIV PrEP Puzzle
- Premature Aging and Age-Related Conditions in People with HIV
- HIV and Aging Experts Release Guidelines for Managing Older People with HIV
- Cobicistat Booster Works as Well as Ritonavir at 48 Weeks
Web Design and Development by